Skip to main content

Table 3 Associations between TIMP-1, Ki-67, HER2 and TOP2A

From: Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

  

TIMP-1 Negative

TIMP-1 Positive

P-value

Ki67

Low

83 (50.6%)

81 (67.5%)

0.004

 

High

81 (49.4%)

39 (32.5%)

 

HER2

Normal*

119 (75.8%)

93 (79.5%)

0.470

 

Amplified

38 (24.2%)

24 (20.5%)

 

TOP2A

Deleted

32 (20.4%)

16 (13.7%)

0.310

 

Normal

110 (70.1%)

91 (77.8%)

 
 

Amplified

15 (9.6%)

10 (8.5%)

 
  1. Normal includes samples with HER2 deletions and HER2 normal samples.